Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...
HKG: 6600
SciClone Pharmaceuticals Gets NMPA Approval for Phase III Study of First-in-Class SERD Orserdu
SciClone Pharmaceuticals Inc. (HKG: 6600), a Chinese pharmaceutical company, has received approval from the National...
GL Capital and SciClone Pharmaceuticals Agree to Privatization and Delisting
GL Capital and SciClone Pharmaceuticals Inc (HKG: 6600) have jointly announced an agreement to privatize...
SciClone and Menarini File for Import License of Antibacterial Drug Vaborem in Macau
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that its Italy-based strategic partner Menarini has submitted...
SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China
SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces...
SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer
SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...
SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China
China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with...
SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group
China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals...
SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study
SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it...
SciClone Pharmaceuticals’ Vaborem Approved for Phase III Clinical Trial in China
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem...
SciClone Pharmaceuticals’ Vaborem IND Filing Accepted by NMPA
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that an Investigational New Drug (IND) filing for...